Adia Nutrition Expands Rapidly, Tripling Sales Force with Regional Teams to Fuel U.S. and Worldwide Growth
Adia Nutrition (OTCQB: ADIA) announced a major expansion of its sales operations by tripling its sales force and establishing four specialized teams. The restructuring creates dedicated teams for the East Coast, West Coast, Central U.S., and national/international markets to promote its Adialabs product line.
The company's portfolio includes AdiaVita (100M umbilical cord stem cells and 3T exosomes per dose), AdiaLink (3.5T exosomes per dose), and Glutaryl Transdermal Glutathione Spray. The expansion aims to enhance market reach and accessibility of these regenerative medicine products to healthcare facilities across the U.S. and globally.
Adia Nutrition (OTCQB: ADIA) ha annunciato una significativa espansione delle sue attività di vendita triplicando la forza vendita e costituendo quattro team specializzati. La riorganizzazione crea gruppi dedicati alla East Coast, West Coast, area centrale degli Stati Uniti e ai mercati nazionali/internazionali per promuovere la linea di prodotti Adialabs.
Il portafoglio dell'azienda comprende AdiaVita (100M cellule staminali da cordone ombelicale e 3T esosomi per dose), AdiaLink (3.5T esosomi per dose) e lo spray transdermico di glutatione Glutaryl. L'espansione punta a migliorare la copertura del mercato e la disponibilità di questi prodotti di medicina rigenerativa presso le strutture sanitarie negli Stati Uniti e a livello globale.
Adia Nutrition (OTCQB: ADIA) anunció una importante expansión de sus operaciones de ventas al triplicar su fuerza de ventas y establecer cuatro equipos especializados. La reestructuración crea equipos dedicados a la costa este, costa oeste, centro de EE. UU. y mercados nacionales/internacionales para promover la línea de productos Adialabs.
El portafolio de la compañía incluye AdiaVita (100M células madre de cordón umbilical y 3T exosomas por dosis), AdiaLink (3.5T exosomas por dosis) y el spray transdérmico de glutatión Glutaryl. La expansión busca ampliar el alcance del mercado y la accesibilidad de estos productos de medicina regenerativa a centros sanitarios en EE. UU. y a nivel global.
Adia Nutrition (OTCQB: ADIA)는 영업 인력을 3배로 확대하고 4개의 전문 팀을 신설하는 대규모 영업 확장을 발표했습니다. 이번 구조조정으로 동부 지역, 서부 지역, 미국 중부 및 국내/국제 시장을 담당하는 전담 팀이 구성되어 Adialabs 제품군을 홍보하게 됩니다.
회사의 포트폴리오에는 AdiaVita(1회 투여분당 제대혈 줄기세포 100M 및 3T 엑소좀), AdiaLink(1회 투여분당 3.5T 엑소좀), 및 Glutaryl 경피 글루타치온 스프레이가 포함됩니다. 이번 확장은 이러한 재생의학 제품들의 시장 접근성과 병원·의료기관에 대한 공급을 미국 전역과 전 세계로 확대하는 것을 목표로 합니다.
Adia Nutrition (OTCQB: ADIA) a annoncé une importante expansion de ses opérations commerciales en triplant ses forces de vente et en mettant en place quatre équipes spécialisées. La restructuration crée des équipes dédiées à la côte Est, côte Ouest, au centre des États-Unis et aux marchés nationaux/internationaux pour promouvoir la gamme de produits Adialabs.
Le portefeuille de la société comprend AdiaVita (100M de cellules souches de cordon ombilical et 3T d'exosomes par dose), AdiaLink (3.5T d'exosomes par dose) et le spray transdermique de glutathion Glutaryl. Cette expansion vise à renforcer la portée du marché et l'accessibilité de ces produits de médecine régénérative aux établissements de santé aux États-Unis et à l'international.
Adia Nutrition (OTCQB: ADIA) gab eine umfangreiche Erweiterung seiner Vertriebsaktivitäten bekannt, indem es seine Vertriebsmannschaft verdreifachte und vier spezialisierte Teams einrichtete. Die Umstrukturierung schafft dedizierte Teams für die Ostküste, Westküste, das zentrale US-Gebiet und nationale/internationale Märkte, um die Adialabs-Produktlinie zu fördern.
Das Portfolio des Unternehmens umfasst AdiaVita (100M Nabelschnur-Stammzellen und 3T Exosomen pro Dosis), AdiaLink (3.5T Exosomen pro Dosis) sowie das transdermale Glutathion-Spray Glutaryl. Die Expansion zielt darauf ab, die Marktreichweite und Verfügbarkeit dieser regenerativen Medizinprodukte für Gesundheitseinrichtungen in den USA und weltweit zu verbessern.
- Tripling sales force size indicates significant business expansion
- Strategic division into four specialized regional teams for focused market penetration
- Growing international presence in key markets like Colombia and Mexico
- Product portfolio includes high-concentration stem cell and exosome formulations
- Sales team structure relies on independent contractors rather than direct employees
- Limited financial metrics provided to assess current market performance
Winter Park, Florida--(Newsfile Corp. - September 9, 2025) - Adia Nutrition, Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine, is excited to announce a rapid expansion of its sales operations by tripling its sales force and creating four specialized teams to accelerate growth and market reach for its innovative Adialabs products. This strategic restructuring divides sales operations into dedicated teams for the East Coast, West Coast, Central U.S., and a team focused on national and international markets.
This expansion reinforces Adia Nutrition's commitment to making its Adialabs products, including AdiaVita (100 million umbilical cord stem cells and 3 trillion exosomes per dose), AdiaLink (3.5 trillion exosomes per dose), Glutaryl Transdermal Glutathione Spray, and all upcoming Adialabs products, more accessible to clinics, doctors, and healthcare facilities across the United States and globally. Each regional sales team will focus on building strong relationships with healthcare providers, using tailored strategies to promote Adialabs' portfolio of regenerative products.
"We are thrilled to triple our sales force and launch four dedicated sales teams to meet the surging demand for Adialabs' innovative products," said Larry Powalisz, CEO of Adia Nutrition, Inc. "By establishing specialized teams for the East Coast, West Coast, Central U.S., and national/international markets, we are positioning Adia Nutrition for rapid growth and delivering exceptional value to healthcare professionals. This structure empowers our sales representatives to forge deeper connections in their regions and drive adoption of AdiaVita, AdiaLink, Glutaryl Transdermal Glutathione Spray, and our exciting pipeline of upcoming products."
The regional sales teams will operate as independent contractors, focusing on high-demand areas for Adialabs products. Meanwhile, the existing national and international sales team will continue to expand Adia Nutrition's global footprint, particularly in markets like the U.S., Colombia, and Mexico, where interest in stem cell and exosome products is growing.
Adia Nutrition's Adialabs products are designed for use in clinical research and are manufactured in compliance with FDA regulations. The Glutaryl Transdermal Glutathione Spray, utilizing advanced sub-nanotechnology for enhanced absorption, is intended for athletes, wellness enthusiasts, and individuals seeking convenient antioxidant support. AdiaVita and AdiaLink are formulated to meet the highest standards for quality and compliance, supporting Adialabs' leadership in regenerative medicine research.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265160
FAQ
What is the significance of Adia Nutrition's (ADIA) sales force expansion in 2025?
What are the main products in Adia Nutrition's (ADIA) portfolio?
How is Adia Nutrition (ADIA) structuring its new sales organization?
What markets is Adia Nutrition (ADIA) targeting for international expansion?
What is the concentration of stem cells in Adia Nutrition's AdiaVita product?
